[1] Schroeder T, Geyh S, Germing U, et al.Mesenchymal stromal cells in myeloid malignancies[J]. Blood Res,2016,51(4):225-232.
[2] Wang J, Xiao Z.Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes[J]. Stem Cell Investig,2014,1:16.
[3] Rathnayake AJ, Goonasekera HW, Dissanayake VH.Phenotypic and Cytogenetic Characterization of Mesen-chymal Stromal Cells in De Novo Myelodysplastic Syndromes[J]. Anal Cell Pathol (Amst),2016,2016:8012716.
[4] Kim Y, Jekarl DW, Kim J, et al.Genetic and epigenetic alterations of bone marrow stromal cells in myelodysplastic syndrome and acute myeloid leukemia patients[J]. Stem Cell Res,2015,14(2):177-184.
[5] Kouvidi E, Stratigi A, Batsali A, et al.Cytogenetic evalua-tion of mesenchymal stem/stromal cells from patients with myelodysplastic syndromes at different time-points during ex vivo expansion[J]. Leuk Res,2016,43:24-32.
[6] Liu Q, Zhu H, Dong J, et al.Defective proliferative potential of MSCs from pediatric myelodysplastic syndrome patients is associated with cell senescence[J]. Int J Clin Exp Pathol,2015,8(10):13059-13066.
[7] Fei CM, Gu SC, Zhao YS, et al.Osteogenic Differentiation Potential of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi,2015,23(3):750-755.
[8] Aanei CM, Flandrin P, Eloae FZ, et al.Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes[J]. Stem Cells Dev,2012,21(10):1604-1615.
[9] Almeida MI, Silva AM, Vasconcelos DM, et al.miR-195 in human primary mesenchymal stromal/stem cells regulates proliferation, osteogenesis and paracrine effect on angiogenesis[J]. Oncotarget,2016,7(1):7-22.
[10] Geyh S, Oz S, Cadeddu RP, et al.Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells[J]. Leukemia,2013, 27(9):1841-1851.
[11] Fei C, Zhao Y, Gu S, et al.Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes[J]. Tumour Biol,2014,35(5):4307-4316.
[12] Fei C, Guo J, Zhao Y, et al.Notch-Hes pathway mediates the impaired osteogenic differentiation of bone marrow mesenchymal stromal cells from myelodysplastic syndromes patients through the down-regulation of Runx2[J]. Am J Transl Res,2015,7(10):1939-1951.
[13] Fei C, Zhao Y, Guo J, et al.Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes[J]. Eur J Haematol,2014,93(6):476-486.
[14] Horiguchi H, Kobune M, Kikuchi S, et al.Extracellular vesicle miR-7977 is involved in hematopoietic dysfunction of mesenchymal stromal cells via poly(rC) binding protein 1 reduction in myeloid neoplasms[J]. Haematologica, 2016,101(4):437-447.
[15] Pavlaki K, Pontikoglou CG, Demetriadou A, et al.Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway[J]. Stem Cells Dev,2014,23(14):1568-1581.
[16] Zhao Y, Wu D, Fei C, et al.Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome[J]. Haematologica,2015,100(2):194-204.
[17] Roversi FM, Lopes MR, Machado-Neto JA, et al.Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion[J]. Stem Cells Dev,2014,23(10):1109-1120.
[18] Poitz DM, Stölzel F, Arabanian L, et al.MiR-134-media-ted β1 integrin expression and function in mesenchymal stem cells[J]. Biochim Biophys Acta,2013,1833(12):3396-3404.
[19] Ferrer RA, Wobus M, List C, et al.Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide[J]. Haematologica,2013,98(11):1677-1685.
[20] Scharenberg C, Giai V, Pellagatti A, et al.Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations[J]. Haematologica,2017,102(3):498-508.
[21] Raaijmakers MH, Mukherjee S, Guo S, et al.Bone progenitor dysfunction induces myelodysplasia and secon-dary leukaemia[J]. Nature,2010,464(7290):852-857.
[22] Raaijmakers MH.Disease progression in myelodysplastic syndromes: do mesenchymal cells pave the way?[J]. Cell Stem Cell,2014,14(6):695-697.
[23] Zou J, Hong Y, Tong Y, et al.Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome[J]. Stem Cells Int,2015,2015:957502.
[24] Medyouf H, Mossner M, Jann JC, et al.Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit[J]. Cell Stem Cell,2014,14(6):824-837.
[25] Schroeder T, Geyh S, Germing U, et al.Mesenchymal stromal cells in myeloid malignancies[J]. Blood Res,2016, 51(4):225-232.
[26] Zambetti NA, Ping Z, Chen S, et al.Mesenchymal Inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia[J]. Cell Stem Cell,2016,19(5):613-627.
[27] Oliveira FM, Lucena-Araujo AR, Favarin Mdo C, et al.Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH[J]. Exp Hematol,2013,41(2):198-208.
[28] Lubkova ON, Tzvetaeva NV, Momotyuk KS, et al.VCAM-1 expression on bone marrow stromal cells from patients with myelodysplastic syndromes[J]. Bull Exp Biol Med,2011,151(1):13-15.
[29] Wang Z, Tang X, Xu W, et al.The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes[J]. PLoS One,2013,8(3):e57470.
[30] Liu LH, Chen H, Chen B, et al.Immuno-suppressive effects on T cells mediated by mesenchymal stem cells from patients with myelodysplastic syndrome[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi,2008,16(2):299-304.
[31] Muntión S, Ramos TL, Diez-Campelo M, et al.Microvesicles from mesenchymal stromal cells are involved in HPC-microenvironment crosstalk in myelodysplastic patients[J]. Plos One,2016,11(2):e0146722.
[32] Xiao Y, Wang Y, Li L, et al.Homing of chloromethylbenzoyl ammonia-labeled bone marrow mesenchymal stem cells in an immune-mediated bone marrow failure mouse model in vivo[J]. Genet Mol Res,2014,13(1):11-21.
[33] Maurizi G, Mattiucci D, Mariani M, et al.DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype[J]. Br J Haematol,2017,177(5):818-822.
[34] Lazarus HM, Haynesworth SE, Gerson SL, et al.Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use[J]. Bone Marrow Transplant,1995,16(4):557-564.
